Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP534168.RAzilNEkygvC5TfzBcBQD1We0YWwvORk_kNPQddGaXhUI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP534168.RAzilNEkygvC5TfzBcBQD1We0YWwvORk_kNPQddGaXhUI130_assertion type Assertion NP534168.RAzilNEkygvC5TfzBcBQD1We0YWwvORk_kNPQddGaXhUI130_head.
- NP534168.RAzilNEkygvC5TfzBcBQD1We0YWwvORk_kNPQddGaXhUI130_assertion description "[When CD34 antibody-binding capacity (ABC) of normal bone marrow (BM) precursors and leukemic blasts was compared, it was shown that AML M2 cases with t(8;21) not only had the highest percentages of CD34+ blasts, but in > 80% of CD34+ cases the individual blasts expressed higher than normal levels of CD34 antigen (> 60 x 10(3) ABC per cell).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP534168.RAzilNEkygvC5TfzBcBQD1We0YWwvORk_kNPQddGaXhUI130_provenance.
- NP534168.RAzilNEkygvC5TfzBcBQD1We0YWwvORk_kNPQddGaXhUI130_assertion evidence source_evidence_literature NP534168.RAzilNEkygvC5TfzBcBQD1We0YWwvORk_kNPQddGaXhUI130_provenance.
- NP534168.RAzilNEkygvC5TfzBcBQD1We0YWwvORk_kNPQddGaXhUI130_assertion SIO_000772 8562943 NP534168.RAzilNEkygvC5TfzBcBQD1We0YWwvORk_kNPQddGaXhUI130_provenance.
- NP534168.RAzilNEkygvC5TfzBcBQD1We0YWwvORk_kNPQddGaXhUI130_assertion wasDerivedFrom befree-20140225 NP534168.RAzilNEkygvC5TfzBcBQD1We0YWwvORk_kNPQddGaXhUI130_provenance.
- NP534168.RAzilNEkygvC5TfzBcBQD1We0YWwvORk_kNPQddGaXhUI130_assertion wasGeneratedBy ECO_0000203 NP534168.RAzilNEkygvC5TfzBcBQD1We0YWwvORk_kNPQddGaXhUI130_provenance.